Avapritinib Therapy
Indication
00937a
As monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy
Abemaciclib Therapy
Indication
00619a
Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.
Abiraterone and prednisoLONE Therapy (mCRPC)
Indication
00103a
Abiraterone is indicated in combination with predniSONE or prednisoLONE for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
00103b
Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
Abiraterone and prednisoLONE Therapy (mHSPC)
Indication
00577a
Abiraterone is indicated with predniSONE or prednisoLONE for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
Afatinib Monotherapy
Indication
00221a
Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Alectinib Monotherapy
Indication
00401a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
00401b
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
00401c
As monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with anaplastic lymphoma kinase (ALK)‑positive NSCLC at high risk of recurrence.
Anastrozole Monotherapy
Indication
00254a
Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.
00254b
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00254c
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Asciminib Therapy
Indication
00847a
Treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP), who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).
Apalutamide Therapy
Indication
00574a
Apalutamide is indicated for the treatment of adult men with nonmetastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
00574b
For the treatment of patients with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
Axitinib Monotherapy
Indication
00104a
Treatment of adult patients with advanced renal cell carcinoma (RCC) after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine
Pembrolizumab 200mg and Axitinib Therapy
Indication
00583a
Pembrolizumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy
Indication
00623a
Treatment of metastatic or unresectable colorectal cancer in patients not suitable for combination chemotherapy with irinotecan or oxaliplatin
Bicalutamide Therapy
Indication
00482a
Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration
Bortezomib, Melphalan and Prednisolone
Indication
00275a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib + Dexamethasone +Thalidomide (VTD) Induction Therapy
Indication
00274a
Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation
Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 21 day
Indication
00416a
Treatment of newly diagnosed myeloma in adult patients with high risk features
00416b
Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features
Bortezomide, Cyclophosphamide and Dexamethasone - 21 day Therapy
Indication
00273a
Treatment of newly diagnosed symptomatic multiple myeloma.
00273b
Treatment of relapsed/refractory multiple myeloma
Bortezomib, Lenalidomide and dexAMETHasone (RVD-Lite) Induction Therapy
Indication
00780a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible C
Pomalidomide ,Bortezomib (Once weekly) and dexamethasone (PVD) - 28 day Therapy
Indication
00880a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy
Indication
00781a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.
Lenalidomide Maintenance Therapy (RVD-Lite)
Indication
00782a
Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.
Bosutinib Monotherapy
Indication
00224a
Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Cabozantinib Therapy
Indication
00518a
Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy
Capecitabine Monotherapy
Indication
00216a
Treatment of patients with locally advanced or metastatic breast cancer
00216b
Treatment of metastatic colorectal cancer.
00216c
Adjuvant treatment of patients following surgery of stage III colon cancer
00216d
Adjuvant treatment of patients following surgery of stage II colon cancer
00216e
Adjuvant treatment of patients with metastatic colorectal cancer following complete resection
Capecitabine and RT - 7 day
Indication
00523a
Locally advanced pancreatic cancer after induction chemotherapy
Capecitabine and Temozolomide Therapy
Indication
00505a
Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.
Capecitabine and Oxaliplatin Therapy (XELOX)
Indication
00321a
Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.
00321b
Treatment of advanced or metastatic colorectal cancer
00321c
Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.
Capecitabine 825mg/m2 and RT - 7 day
Indication
00586a
Locally advanced rectal cancer
Capivasertib and Fulvestrant Therapy
Indication
00947a
In combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER) positive, HER2 negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN-alteration following recurrence or progression on or after an endocrine-based regimen.
In pre- or peri-menopausal females, therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
CARBOplatin and Oral Etoposide Therapy - 21 days
Indication
00319a
Small cell lung cancer (SCLC) extensive disease
Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
Indication
00405a
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Carfilzomib and dexAMETHasone (Kd) Therapy - 28 day
Indication
00566a
In combination with dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Carfilzomib (56mg/m2 once weekly) Lenalidomide and dexAMETHasone (KRd) Therapy - 28 day
Indication
00598a
Carfilzomib, lenalidomide and dexAMETHasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Ceritinib Monotherapy
Indication
00340a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
Chlorambucil10mg/m2 Therapy
Indication
00411a
Treatment of patients with low grade lymphoma.
00411b
Treatment of patients with Chronic Lymphocytic Leukaemia
CISplatin and Capecitabine Adjuvant Chemoradiation Therapy
Indication
00473a
Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases
CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day
00279a
Small cell lung cancer (SCLC) limited disease
00279b
Small cell cancer of the cervix and other sites
CISplatin (75mg/m2) + Etoposide Therapy - 21 day
00280a
Small cell lung cancer (SCLC) extensive disease
CISplatin and Teysuno-28 day cycle
Indication
00235a
Treatment of advanced gastric cancer when given in combination with CISplatin.
Cobimetinib and Vemurafenib Therapy
Indication
00373a
Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Crizotinib Monotherapy
Indication
00243a
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
00243b
The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)
00243c
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
cyloPHOSphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
Indication
00377a
Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy
00377b
Metastatic breast carcinoma
Dabrafenib Monotherapy
Indication
00237a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Dacomitinib Monotherapy
Indication
00565a
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations
Darolutamide Therapy
Indication
00693a
Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
Daratumumab SC, Lenalidomide and dexAMETHasone Therapy
Indication
00854a
Daratumumab in combination with lenalidomide and dexAMETHasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy
Indication
00532a
Treatment of Symptomatic treatment naive or relapsed/refractory Waldenstrom’s macroglobulinaemia
Encorafenib and Binimetinib Therapy
Indication
00563a
Treatment of adult patients with advanced unresectable or metastatic) melanoma with a BRAF V600 mutation.
Enzalutamide Monotherapy
Indication
00233a
Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after DOCEtaxel therapy.
00233b
Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
00233c
The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)
Erdafitinib Monotherapy
Indication
00885a
As monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.
epiRUBicin, CISplatin and Capecitabine (ECX) Therapy
Indication
00380a
Perioperative treatment of resectable gastric adenocarcinoma
00380b
Perioperative treatment of resectable gastroesophageal junction adenocarcinoma
00380c
Perioperative treatment of resectable lower oesophagus adenocarcinoma
00380d
Palliative therapy for metastatic or locally advanced gastric adenocarcinoma
00380e
Palliative therapy for metastatic or locally advanced oesphagogastric adenocarcinoma
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy - 21 day
Indication
00239a
Locally advanced or metastatic gastric carcinoma
00239b
Locally advanced or metastatic oesophageal carcinoma
00239c
Locally advanced or metastatic gastroesophageal carcinoma
Erlotinib Monotherapy
Indication
00219a
First-line treatment of patients with locally advanced or metastatic non - small cell lung cancer (NSCLC) with EGFR activating mutations.
00219b
Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy
00219c
Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
Escalated Dose BEACOPP 21 day Therapy
Indication
00354a
Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)
00354b
Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD
Everolimus Monotherapy
Indication
00320a
Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy
00320b
Treatment of unresectable or metastatic, well or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
00320c
The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease
Exemestane Monotherapy
Indication
00376a
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00376b
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy.
00376c
Advanced breast cancer after relapse or disease porgression in women with natural or artificially induced post menopausal endocrine status
Everolimus and Exemestane Therapy
Indication
00322a
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Fruquintinib Monotherapy
Indication
00890a
As monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
Fedratinib Therapy
Indication
00788a
For the treatment of disease-related splenomegaly or symptoms in adult patients with:
primary myelofibrosis (PMF),
post polycythaemia vera myelofibrosis (PVMF) or
post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib
Gefitinib Monotherapy
Indication
00220a
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK
Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days
Indication
00524a
Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection
Gemcitabine (1000mg/m2) and Capecitabine (650mg/m2) Therapy - 21
Indication
00384a
Locally advanced or metastatic pancreatic carcinoma.
00384b
Locally advanced biliary tree carcinoma.
Gilteritinib Therapy
Indication
00684a
As monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.
Hydroxycarbamide Therapy
Indication
00581a
Treatment for patients with high risk myeloproliferative neoplasms
00581b
Treatment of leucocytosis in AML and CML
Hyper CVAD (ALL) Maintenance Therapy (POMP)
00912a
Maintenance therapy for adult patients ≥ 25 years with Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
00912b
Maintenance therapy for adult patients ≥ 25 years with Ph negative acute lymphoblastic lymphoma
Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)
Indication
00296a
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00296b
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy
00296c
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy
Ibrutinib Therapy - Mantle Cell Lymphoma
Indication
00297a
As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
Idelalisib and Ofatumumab Therapy
Regimen
Indication
00390a
In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00390b
In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies
Idelalisib Monotherapy
Indication
00291a
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Imatinib Therapy-GIST
Indication
00335a
Treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
00335b
Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST
Ivosidenib Therapy
Indication
00901a
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.
Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day
Indication
00516a
Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Larotrectinib Monotherapy - Adult
Indication
00758a
For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
Larotrectinib Monotherapy - Paediatric
Indication
00760a
For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
Lapatinib and Capecitabine Therapy
Indication
00217a
Treatment of adult patients with breast cancer, whose tumours over express HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting
LEAM Autologous Transplant Conditioning Protocol (Lomustine, etoposide, cytarabine, melphalan)
Indication
00468a
Autologous conditioning in non-Hodgkins Lymphoma (NHL)
00468b
Autologous conditioning in Hodgkins lymphoma
Lenalidomide 25mg and Dexamethasone Therapy - 28 day
Indication
00218a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant
00218b
Treatment of multiple myeloma in adult patients who have received at least one prior therapy
Lenvatinib DTC Therapy
Indication
00295a
Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
Lenvatinib - HCC Therapy
Indication
00644a
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
Letrozole Monotherapy
Indication
00371a
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00371b
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.
00371c
Advanced breast cancer after relapse or disease progression in women with natural or artificially induced post menopausal endocrine status
00371d
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
00371e
First-line treatment in postmenopausal women with hormone dependent advanced breast cancer.
Lomustine 130mg/m2 Therapy
Indication
00805a
Recurrent malignant glioma
Lorlatinib Therapy
Indication
00570a
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on
(i) alectinib or ceritinib as the first ALK-targeted treatment or
(ii) crizotinib and at least one other ALK-targeted treatment
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Indication
00682a
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy
Indication
00661a
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy
Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone - Weekly Therapy
Indication
00299a
Treatment of newly diagnosed symptomatic multiple myeloma
00299b
Treatment of relapsed/refractory multiple myeloma
Neratinib Therapy
Indication
00720a
Extended adjuvant treatment of adults with early-stage hormone receptorpositive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
Nindetanib Therapy
Indication
00372a
Treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy
Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy
Indication
00848a
Niraparib in combination with abiraterone acetate (Akeega®) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
Niraparib (Tablets) Monotherapy
Indication
00862a
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862b
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862c
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862d
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00862e
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) fallopian tube cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00862f
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Obinutuzumab and Chlorambucil Therapy
Indication
00286a
Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
Olaparib (Tablet) Monotherapy
Indication
00588a
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588b
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588c
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588d
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) -high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588e
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588f
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588g
As monotherapy for the treatment of adult patients with metastatic castrationresistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
00588h
As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
00588i
As monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Oral Etoposide Therapy
Indication
00388a
Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy
Oral Vinorelbine Monotherapy-7days
Indication
00259a
Advanced breast cancer
00259b
Non small cell lung cancer (NSLC)
Osimertinib Monotherapy
Indication
00353a
Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
00353b
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
00353c
As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.
Palbociclib Therapy-28 day
Indication
00414a
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor
00414b
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
Pemigatinib Therapy
Indication
00889a
As monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Pazopanib Therapy
Indication
00445a
First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.
00445b
Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Pomalidomide and Dexamethasone
Indication
00245a
Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Pomalidomide, Bortezomib and dexAMETHasone (PVD) Therapy
Indication
00601a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
Pomalidomide, Bortezomib (Once weekly) and dexamethasone (PVD) - 28 day Therapy
Indication
00880a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
PONATinib Therapy
Indication
00302a
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
00302b
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Procarbazine Lomustine and VinCRIStine (PCV) Therapy
Indication
00379a
Adjuvant treatment of Grade II glioma administered after radiotherapy
00379b
Palliative treatment for recurrent high grade gliomas
Procarbazine, Lomustine and VinCRIStine (PCV) Therapy - 56 days
Indication
00658a
Adjuvant treatment of Grade II glioma administered after radiotherapy
Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy
Indication
00886a
Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy
Indication
00887a
Quizartinib in combination with cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Quizartinib, IDArubicin and Cytarabine Induction Therapy
Indication
00891a
Quizartinib in combination with standard IDArubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive
Quizartinib Maintenance Therapy
Indication
00888a
As monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.
R-CEOP Therapy - 21 days
Indication
00510a
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.
Regorafenib Monotherapy
Indication
00244a
Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
00244b
Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib
Relugolix Therapy
Indication
00830a
Treatment of adult patients with advanced hormone-sensitive prostate cancer (HSPC).
Ribociclib Therapy - (Metastatic) 28 day
Indication
00525a
Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.
00525b
Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.
In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
Ribociclib Therapy (Adjuvant) - 28 day
Indication
00892a
In combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence
Rucaparib (Tablets) Monotherapy
Indication
00904a-c
As monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV)
- high-grade epithelial ovarian,
- fallopian tube, or
- primary peritoneal cancer
who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Ruxolitinib Monotherapy
Indication
00229a
Treatment of disease related splenmegaly or symptoms in adult patients with primary myelofibrosis (chronic idiopathic myelofibrosis)
00229b
Post polycythaemia vera myelofibrosis
00229c
Post essential thrombocythaemia myelofibrosis
SORAfenib Therapy
Indication
00294a
Treatment of hepatocellular carcinoma (HCC).
00294b
Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
00294c
Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
SUNitnib 37.5mg Therapy - 28 days
Indication
00327a
Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults
SUNitinib 50mg Therapy - 42 days
Indication
00325a
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
00325b
Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults
SUNitinib 50mg Therapy (21 days)
Indication
00719a
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
00719b
Treatment of clear-cell type metastatic renal cell carcinoma (MRCC).
Talazoparib Therapy
Indication
00605a
Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.
Tamoxifen Monotherapy
Indication
00253a
Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.
00253b
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women
Temozolomide Recurrent Therapy
Indication
00342a
Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma,showing recurrence or progression after standard therapy.
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years
Indication
00461a
Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide.
Temozolomide with RT and Adjuvant Therapy
Indication
00334a
Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation.
Tepotinib Therapy
Indication
00823a
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy
Tivozanib Therapy
Indication
00564a
Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC
Topotecan Oral Monotherapy
Indication
00587a
Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first –line regimen is not considered appropriate
Trametinib and Dabrafenib Therapy
Indication
00415a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy
Indication
00356a
Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL)(defined as WCC count ≤ 10x109/L)
00356b
Treatment of adult patients with relapsed or refractory APL after ATRA/chemotherapy
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Indication
00357a
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356
Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy
Indication
00366a
Treatment of patients with newly diagnosed Acute Promyelocytic Leukaemia (APL)
Trifluridine and Tipiracil (Lonsurf®) Therapy
Indication
00382a
Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based therapies, anti-VEGF and anti-EGFR agents.
Tucatinib, Trastuzumab and Capecitabine Therapy
Indication
00936a
Tucatinib in combination with trastuzumab and capecitabine, for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
UKALL14 Phase 1 Standard Induction Therapy
Indication
00874a
Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25–65 years) treated on UKALL14-protocol.
UKALL14 Phase 2 Standard Induction Therapy
Indication
00875a
Induction of remission in newly diagnosed previously untreated Adult Acute Lymphoblastic Leukaemia (ALL) patients (aged 25 - 65 years) treated on UKALL14-protocol following Phase 1 Induction Therapy
UKALL 14 Intensification/CNS Prophylaxis Therapy
Indication
00876a
Treatment of adult patients (aged 25 - 65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) following Phase 2 Induction Therapy
UKALL14v12 Consolidation Phase Cycle 1
Indication
00877a
Treatment of adult patients (aged 25 - 65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) treated on UKALL14-protocol who are in remission but not eligible for allogeneic transplantation following treatment with Intensification/CNS Prophylaxis regimen
UKALL14v12 Consolidation Phase Cycle 2 and 4
Indication
00878a
Treatment of adult patients(aged 25 - 65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) treated on UKALL14-protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase 1 (for Cycle 2) and Consolidation Phase 3 (for Cycle 4)
UKALL14v12 Consolidation Phase Cycle 3
Indication
00879a
Treatment of adult patients (aged 25 - 65 years) with newly diagnosed, previously untreated Acute Lymphoblastic Leukaemia (ALL) treated on UKALL14- protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase 2
UKALL14v12 Maintenance Therapy
Indication
00881a
Treatment of adult patients (aged 25 - 65 years) with newly diagnosed, previously untreated Acute Lymphoblastic Leukaemia (ALL) treated on UKALL14- protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase Cycle 4
Vandetanib Monotherapy
Indication
00242a
Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Vemurafenib Monotherapy
Indication
00102a
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Venetoclax Monotherapy
Indication
00400a
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor
00400b
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor
Venetoclax and Rituximab Therapy
Indication
00575a
Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Vismodegib Monotherapy
Indication
00236a
Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)
00236b
Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
Zanubrutinib Therapy
Indication
00708a
As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or as first line treatment for patients unsuitable for chemo-immunotherapy
00708b
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naïve and have del(17p) and/or TP53-mutated disease
00708c
As monotherapy for the treatment of adult patients with CLL, who have relapsed and/or refractory disease following at least one line of prior therapy
00708d
As monotherapy for the treatment of adult patients with relapsed/refractory marginal zone lymphoma, who have received at least one prior anti-CD20-based therapy